186 related articles for article (PubMed ID: 10138727)
1. The Chinese medicines market: moving towards a market system?
Huttin C
Health Policy; 1994 Sep; 29(3):247-59. PubMed ID: 10138727
[TBL] [Abstract][Full Text] [Related]
2. [Competition and prices in the Mexican pharmaceutical market].
Molina-Salazar RE; González-Marín E; Carbajal-de Nova C
Salud Publica Mex; 2008; 50 Suppl 4():S496-503. PubMed ID: 19082261
[TBL] [Abstract][Full Text] [Related]
3. A Case Study of Pharmaceutical Pricing in China: Setting the Price for Off-Patent Originators.
Hu S; Zhang Y; He J; Du L; Xu M; Xie C; Peng Y; Wang L
Appl Health Econ Health Policy; 2015 Aug; 13 Suppl 1(Suppl 1):S13-20. PubMed ID: 26091710
[TBL] [Abstract][Full Text] [Related]
4. Differential pricing for pharmaceuticals: reconciling access, R&D and patents.
Danzon PM; Towse A
Int J Health Care Finance Econ; 2003 Sep; 3(3):183-205. PubMed ID: 14625999
[TBL] [Abstract][Full Text] [Related]
5. The consumer welfare implications of governmental policies and firm strategy in markets for medicines.
Chatterjee C; Kubo K; Pingali V
J Health Econ; 2015 Dec; 44():255-73. PubMed ID: 26581076
[TBL] [Abstract][Full Text] [Related]
6. Pharmaceutical pricing: an empirical study of market competition in Chinese hospitals.
Wu J; Xu J; Liu G; Wu J
Pharmacoeconomics; 2014 Mar; 32(3):293-303. PubMed ID: 24190661
[TBL] [Abstract][Full Text] [Related]
7. Impacts of regulated competition on pricing in Chinese pharmaceutical market under urban employee basic medical insurance.
Zhao M; Wu J
Expert Rev Pharmacoecon Outcomes Res; 2017 Jun; 17(3):311-320. PubMed ID: 27762144
[TBL] [Abstract][Full Text] [Related]
8. [An analysis of the pharmaceuticals market in Vietnam].
Simonet D
Sante; 2001; 11(3):155-60. PubMed ID: 11641078
[TBL] [Abstract][Full Text] [Related]
9. The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.
Kesselheim AS; Avorn J; Sarpatwari A
JAMA; 2016 Aug 23-30; 316(8):858-71. PubMed ID: 27552619
[TBL] [Abstract][Full Text] [Related]
10. Secondary patents in the pharmaceutical industry: missing the wood for the trees?
Kiran S; Kulkarni M
Expert Opin Ther Pat; 2018 Mar; 28(3):241-250. PubMed ID: 29298119
[TBL] [Abstract][Full Text] [Related]
11. Price regulation of pharmaceuticals in Canada.
Anis AH; Wen Q
J Health Econ; 1998 Jan; 17(1):21-38. PubMed ID: 10176313
[TBL] [Abstract][Full Text] [Related]
12. Pharmaceutical policy in the Netherlands: from price regulation towards managed competition.
Boonen LH; van der Geest SA; Schut FT; Varkevisser M
Adv Health Econ Health Serv Res; 2010; 22():53-76. PubMed ID: 20575228
[TBL] [Abstract][Full Text] [Related]
13. [Impact Reimbursement Act on the pharmaceutical market in Poland].
Giermaziak W
Pol Merkur Lekarski; 2014 Apr; 36(214):270-3. PubMed ID: 24868902
[TBL] [Abstract][Full Text] [Related]
14. Pharmaceutical policy in Italy: towards a structural change?
Ghislandi S; Krulichova I; Garattini L
Health Policy; 2005 Apr; 72(1):53-63. PubMed ID: 15760698
[TBL] [Abstract][Full Text] [Related]
15. Ownership of knowledge--the role of patents in pharmaceutical R&D.
Correa CM
Bull World Health Organ; 2004 Oct; 82(10):784-7; discussion 787-90. PubMed ID: 15643801
[TBL] [Abstract][Full Text] [Related]
16. Reanalyzing reverse payment settlements: a solution to the patentee's dilemma.
Wang Z
Cornell Law Rev; 2014 Jul; 99(5):1227-58. PubMed ID: 25112001
[No Abstract] [Full Text] [Related]
17. The shifting functional balance of patents and drug regulation.
Eisenberg RS
Health Aff (Millwood); 2001; 20(5):119-35. PubMed ID: 11558697
[TBL] [Abstract][Full Text] [Related]
18. Health policy versus industrial policy in the pharmaceutical sector: the case of Canada.
Vandergrift M; Kanavos P
Health Policy; 1997 Sep; 41(3):241-60. PubMed ID: 10170092
[TBL] [Abstract][Full Text] [Related]
19. Legal and policy foundations for global generic competition: Promoting affordable drug pricing in developing societies.
Zapatero Miguel P
Glob Public Health; 2015; 10(8):901-16. PubMed ID: 25737069
[TBL] [Abstract][Full Text] [Related]
20. The effect of generic competition on the price of brand-name drugs.
Lexchin J
Health Policy; 2004 Apr; 68(1):47-54. PubMed ID: 15033552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
